EnviroGold Global Ltd
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 1.2K
- Market Cap
- -
- Introduction
Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
Sacroiliac (SI) Joint Transfixing and Fusion: Meaningful Long Term Outcomes With Nevro1
- Conditions
- Sacroiliac Joint Dysfunction
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Nevro Corp
- Target Recruit Count
- 180
- Registration Number
- NCT06909292
- Locations
- πΊπΈ
AIRS Clinic, Lodi, California, United States
πΊπΈMichigan Orthopaedic Surgeons, Southfield, Michigan, United States
πΊπΈCarolinas Pain Institute, Winston-Salem, North Carolina, United States
Clinical Trial of MED HF10β’ Spinal Cord Stimulation for the Treatment of Chronic Pain
- Conditions
- Chronic, Intractable Back Pain And/or Leg Pain
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Nevro Corp
- Target Recruit Count
- 25
- Registration Number
- NCT06897280
- Locations
- πΊπΈ
Neuroscience Research Center, Overland Park, Kansas, United States
Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
- Conditions
- Painful Diabetic Neuropathy
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Nevro Corp
- Target Recruit Count
- 143
- Registration Number
- NCT05777317
- Locations
- πΊπΈ
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
πΊπΈTouchstone Interventional Pain Center, Medford, Oregon, United States
PDN Post Market, Multicenter, Prospective, Global Clinical Study
- Conditions
- Diabetic Neuropathy, Painful
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Nevro Corp
- Target Recruit Count
- 497
- Registration Number
- NCT05301816
- Locations
- πΊπΈ
WellSpan Interventional Pain Specialists, York, Pennsylvania, United States
πΊπΈNeuroversion, Inc., Anchorage, Alaska, United States
πΊπΈMichigan Pain Specialists, Ann Arbor, Michigan, United States
HF10 Treatment of Chronic Knee Pain
- Conditions
- Chronic Pain Post-Procedural
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Nevro Corp
- Target Recruit Count
- 3
- Registration Number
- NCT04020211
- Locations
- πΊπΈ
Pain Management, Greenfield, Wisconsin, United States
- Prev
- 1
- 2
- Next
News
Nevro's HFX iQ Spinal Cord Stimulation System Receives CE Mark for Personalized Pain Relief
Nevro's HFX iQ spinal cord stimulation (SCS) system, leveraging AI and high-frequency therapy, has secured CE mark in Europe for personalized pain relief.
Nevro's AI-Powered Spinal Cord Stimulation System, HFX iQ with AdaptivAI, Receives FDA Approval
Nevro's HFX iQ with AdaptivAI, an AI-driven spinal cord stimulation system, has gained FDA approval for chronic pain management.